Medium 254CF, Kit

Mammalian cell culture media Human Epidermal Melanocytes: HEM

Experiment
Mammalian cell culture media Human Epidermal Melanocytes: HEM
Product
Medium 254CF, Kit from Thermo Fisher Scientific
Manufacturer
Thermo Fisher Scientific

Protocol tips

Protocol tips
supplement M-254 medium with HMGS-2, penicillin (100 U/ml), gentamicin (10 µg/ml) and amphotericin B (0.25 µg/ml) and culture the cells at 37°C in 5% CO2.

Publication protocol

The normal human epidermal melanocytes (HEMaLP, Cascade Biologists) were grown according to the
manufacturer’s instruction. The cells were cultured in
M-254 medium supplemented with HMGS-2, penicillin (100 U/ml), gentamicin (10 µg/ml) and amphotericin B (0.25 µg/ml) at 37°C in 5% CO2. All experiments were performed using cells in the passages 5–7.

Full paper   Login or join for free to view the full paper.

Reviews

Medium 254CF, Kit from Thermo Fisher Scientific has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing Mammalian cell culture media Human Epidermal Melanocytes: HEM using Medium 254CF, Kit from Thermo Fisher Scientific.

Paper title
Cytotoxic effect of lomefloxacin in culture of human epidermal melanocytes.
Full paper
Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from Thermo Fisher Scientific for Medium 254CF, Kit below.

Download PDF Download manufacturer protocol

Videos

Check out videos that might be relevant for performing Mammalian cell culture media Human Epidermal Melanocytes: HEM using Medium 254CF, Kit from Thermo Fisher Scientific. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Become shareholder Discussions About us Contact Privacy Terms